Regulus Therapeutics' microRNA technology may be risky given its relative newness, but that hasn't kept stodgy pharmaceutical companies from stepping up to the plate. In less than three years since the company was formed by Isis Pharmaceuticals
After a pair of deals with GlaxoSmithKline
Any drugs coming out of the partnership will be taken through the clinic by sanofi with Regulus getting milestone payments and royalties on any drugs that make it to market. All told the deal could be worth $750 million, although it'll start with just a $25 million upfront fee and a $10 million equity investment.
Regulus' parent companies get 7.5% of the initial payment and the future milestone payments. Not a lot of cash, but every bit helps when you don't have significant revenue coming in.
Whether you're better off buying Alnylam or Isis to get a piece of Regulus depends on your risk tolerance. Alnylam is the smaller company, so Regulus makes up a larger percentage of its value. Isis' pipeline is more developed, offering slightly lower risk. Isis' lead drug, mipomersen, partnered with Genzyme
If you do decide to invest, just keep in mind that microRNA therapies are years away from being approved for sale, and plenty of interesting technologies have fizzled out without producing many -- or even any -- useful drugs. Glaxo and sanofi can afford to take a risk on the technology because microRNA therapies are part of their diversified portfolios of drug candidates. Foolish investors looking to invest in microRNAs should do the same.
More from The Motley Fool
Will 2018 Be Alnylam Pharmaceuticals, Inc.'s Best Year Yet?
There's a lot of good news potentially on the way for the biotech. But its 2017 performance will be hard to beat.
Will 2018 Be Ionis Pharmaceuticals, Inc.'s Best Year Yet?
Here's why 2018 could be a banner year for this pioneering biotech and its recent spinoff.
This Is Why Alnylam Pharmaceuticals Soared 249% in 2017
It was a breakout year for the clinical-stage biotech.